Purified virus stock (preparation and characterization)

The Food and Drug Administration seeks proposals to prepare and characterize purified virus stocks for use as reagents in assessing next-generation sequencing platforms. The solicitation requires 1,000 vials each of six specified virus types meeting minimum technical requirements for titers, genome copy numbers, sterility, and mycoplasma testing. Offerors must demonstrate the capability for long-term temperature-controlled storage of the virus stocks. Proposals are due by June 23, 2020 and will be evaluated based on technical approach, past performance, and price. The period of performance is 12 months from date of award.

The contract has no set-aside designation. The primary NAICS code is 541711 and PSC code is R425. The place of performance is within the United States. The solicitation is for a firm-fixed-price commercial item contract with a total value between $500,000-$1,000,000 over a 60 month period including an initial 12 month base period for preparation and characterization of 5 shipments of 20 vials each of the six virus stocks, and four 1-year option periods for storage and up to 5 domestic and 5 international shipments annually of each virus stock.